A combined Phase IIa / IIb study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naive subjects with neovascular age related macular degeneration
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2018
Price : $35 *
At a glance
- Drugs Regorafenib (Primary) ; Ranibizumab
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms DREAM
- Sponsors Bayer
- 20 Oct 2018 Results published in the British Journal of Clinical Pharmacology
- 25 Jul 2016 Status changed from completed to discontinued.
- 14 Aug 2015 According to the ClinicalTrials.gov record, status changed from recruiting to completed.